Get started
Author

Hidenori Fujita

Observed name: H. Fujita
ORCID: 0000-0002-1170-3284
Observed ORCID: 0000-0002-1170-3284
OpenAlex ID: A5087098741
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
2020 · Hiroshi Sootome, Hidenori Fujita, et al. · Cancer Research · 220
PDF
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
2023 · Isao Miyazaki, Igor Odintsov, et al. · Nature Cancer · 48
PDF
The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2013 · Hidenori Fujita, Kazutaka Miyadera, et al. · Molecular Cancer Therapeutics · 38
Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.
2013 · Hiroaki Ochiiwa, Hidenori Fujita, et al. · Molecular Cancer Therapeutics · 28
The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer
2016 · Kenta Watanabe, Michiko Hirata, et al. · Journal of Biological Chemistry · 26
PDF
High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells
2016 · Hidenori Fujita, Akira Gomori, et al. · PLoS ONE · 21
PDF
Abstract P06-02: Discovery of TAS0953/HM06, a novel next generation RET-specific inhibitor capable of inhibiting RET solvent front mutations
2021 · Isao Miyazaki, Keiji Ishida, et al. · Molecular Cancer Therapeutics · 11
Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors .
2013 · Hiroshi Sootome, Yayoi Fujioka, et al. · Molecular Cancer Therapeutics · 11
Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy
2023 · Toshihiro Shibutani, Risa Goto, et al. · Scientific Reports · 3
PDF
438 Identification of Gene Expression Signature to Predict Anti-tumor Efficacy of MET/VEGFR Inhibitor, TAS-115
2012 · H. Itadani, S. Hasako, et al. · European Journal of Cancer · 3
First-in-human study of TAS-115, a novel oral MET/VEGFR inhibitor, in patients with advanced solid tumors.
2015 · Nobuaki Matsubara, Kohei Shitara, et al. · Journal of Clinical Oncology · 2
Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.
2013 · Yoko Nakatsuru, Hiroaki Ochiiwa, et al. · Molecular Cancer Therapeutics · 2
Abstract 3577: TAS-115: a highly potent c-Met + VEGFRs dual inhibitor with prominently safer profile
2011 · Hidenori Fujita, Kazutaka Miyadera, et al. · Cancer Research · 2
Abstract 3600: The prominent safety profile of TAS-115, a novel c-Met + VEGFR dual kinase inhibitor can lead to potentiate the efficacy via durable inhibition of angiogenesis
2011 · Hiroaki Ochiiwa, Hidenori Fujita, et al. · Cancer Research · 2
Author Correction: Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy
2024 · Toshihiro Shibutani, Risa Goto, et al. · Scientific Reports · 1
PDF
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
2023 · Isao Miyazaki, Igor Odintsov, et al. · Nature Cancer · 1
PDF
Data from Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
2023 · Hiroshi Sootome, Hidenori Fujita, et al. · 1
Abstract 4784: TAS0286/HM05, a novel highly selective RET inhibitor, prominently inhibits various RET defective tumor growth
2018 · Hidenori Fujita, Isao Miyazaki, et al. · Cancer Research · 1
Abstract 1785: MET/VEGFR dual inhibition and prominent safety profile of TAS-115 are favorable for the combination with chemotherapeutic drugs
2012 · Hidenori Fujita, Masanori Kato, et al. · Cancer Research · 1
Data from The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2023 · Hidenori Fujita, Kazutaka Miyadera, et al.
Data from The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2023 · Hidenori Fujita, Kazutaka Miyadera, et al.
Supplementary Figures 1 through 5 and Supplementary Tables 1 through 3 from The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2023 · Hidenori Fujita, Kazutaka Miyadera, et al.
PDF
Data from Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
2023 · Hiroshi Sootome, Hidenori Fujita, et al.
Supplementary Data from Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
2023 · Hiroshi Sootome, Hidenori Fujita, et al.
Supplementary Data from Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
2023 · Hiroshi Sootome, Hidenori Fujita, et al.
Works count: 35
Citation count: 422
H-index: 8
I10-index: 8
Year
Topic
Type